Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Halobetasol Propionate · Bryhali, Lexette

Small molecule · developed by Sun Pharm Inds

Approved FDA, Dec 1990
1 Registered trials

What is Halobetasol Propionate?

Halobetasol propionate is a topical corticosteroid that plays a role in cellular signaling, immune function, inflammation, and protein regulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Bryhali, Lexette, Ultravate, BMY-30056, CGP-14458
Drug type
Small molecule
Therapy area
Dermatology
Developer
Sun Pharm Inds Inc
In trials of
BHC
FDA status
Approved as Bryhali, Lexette, Ultravate (December 17, 1990), NDA019968 · FDA label
UNII
91A0K1TY3Z

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 6, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05608499 Phase 3 Acne Keloidalis Nuchae Terminated BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne Keloidalis NuchaeAKN

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.